Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

Pages

32 results
5:33 PM, Oct 19, 2017  |  BC Week In Review | Company News  |  Deals

Chiesi licenses Protalix's Fabry's disease candidate

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) ex-U.S. rights to pegunigalsidase alfa
PRX-102), which is in Phase III testing to treat Fabry's disease. Protalix will receive $25 million …
320 million in regulatory and commercial milestones, plus royalties. Protalix will maintain full rights to PRX-102
3:00 PM, Mar 02, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

Amicus sales and marketing update

Galafold is one capsule taken every other day. Galafold is a small molecule that enhances alpha galactosidase
1:37 PM, Jan 06, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

Galafold sales and marketing update

replacement therapy (ERT). The biotech said it plans to launch the small molecule that enhances alpha galactosidase
12:00 AM, Oct 31, 2016  |  BC Week In Review | Company News  |  Sales & Marketing

Amicus Therapeutics sales and marketing update

of whom about 140 would be suitable for treatment with the small molecule that enhances alpha galactosidase
12:00 AM, Mar 28, 2016  |  BC Week In Review | Company News  |  Sales & Marketing

Amicus Therapeutics sales and marketing update

ANSM) has granted an Authorization of Temporary Use (ATU) of the small molecule that enhances alpha galactosidase
12:00 AM, Feb 22, 2016  |  BC Week In Review | Company News  |  Deals

University Health Network, Avrobio deal

IL-12. The Fabry’s candidate, AVR-02 , contains autologous CD34+ hematopoietic stem cells modified to express alpha-galactosidase
12:00 AM, Sep 07, 2015  |  BC Week In Review | Company News  |  Deals

Scioderm, Amicus Therapeutics deal

Amicus is planning to submit an NDA this half for the small molecule that enhances alpha galactosidase
12:00 AM, Nov 03, 2014  |  BC Week In Review | Company News  |  Other News

greenovation endocrine/metabolic news

manufactured in moss for clinical use. The substance, greenovation's Moss-aGal , is a recombinant human alpha-galactosidase
12:00 AM, Oct 06, 2014  |  BC Week In Review | Company News  |  Deals

BioProtein, Pharming deal

founder rabbits producing recombinant human versions of acid alpha glucosidase (GAA) to treat Pompe's disease; alpha galactosidase
12:00 AM, Aug 18, 2014  |  BC Week In Review | Company News  |  Deals

Evotec, Shire deal

optimization. Evotec said financial terms are not disclosed. Shire markets Replagal agalsidase alfa, an injectable alpha galactosidase

Pages